H. Schreiber

发表

TUMOR NECROSIS FACTOR/CACHECTIN InductionofHemorrhagic NecrosisinNormal TissueRequires the FifthComponent ofComplement (C5)

H. Schreiber, 2007 .

Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5)

T. Lint, H. Schreiber, J. Rothstein, 1988, The Journal of experimental medicine.

Relationship of tumour necrosis factor and endotoxin to macrophage cytotoxicity, haemorrhagic necrosis and lethal shock.

H. Schreiber, J. Rothstein, 1987, Ciba Foundation symposium.

Differentiation by TICAS analysis of cell populations of tracheal aspirates from hamsters with squamous-cell carcinoma.

P. Bartels, M. Bibbo, G. Wied, 1979, American Journal of Clinical Pathology.

Innate and adaptive immune cells in the tumor microenvironment

H. Schreiber, yang-xin fu, T. Gajewski, 2013, Nature Immunology.

LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models.

K. Mangold, P. Seth, B. Prabhakar, 2020, Human gene therapy.

Classification of current anticancer immunotherapies

Axel Hoos, Patrizia Agostinis, Fernando Aranda, 2014, Oncotarget.

Priming of naive T cells inside tumors leads to eradication of established tumors

Youjin Lee, H. Schreiber, yang-xin fu, 2004, Nature Immunology.

Specificity in cancer immunotherapy.

Hans Schreiber, H. Schreiber, M. Philip, 2008, Seminars in immunology.

In vivo administration of anti-CD3 prevents malignant progressor tumor growth.

J. Bluestone, H. Schreiber, J. Ellenhorn, 1988, Science.

Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity.

H. Schreiber, P. Flood, X. Liu, 1998, Journal of immunotherapy.

Antigenic cancer cells that escape immune destruction are stimulated by host cells.

H. Schreiber, S. Seung, L. Seung, 1995, Cancer research.

Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases1

Youjin Lee, H. Schreiber, yang-xin fu, 2007, The Journal of Immunology.

Pharmacokinetic Differences Between a T Cell-Tolerizing and a T Cell-Activating Peptide1

H. Schreiber, S. Meredith, W. Kast, 2001, The Journal of Immunology.

PeptideCell-Tolerizing and a T Cell-Activating Pharmacokinetic Differences Between a T

H. Schreiber, S. Meredith, W. Kast, 2001 .

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

H. Koeppen, B. Park, H. Koeppen, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

J. Bluestone, Lieping Chen, H. Koeppen, 1997, The Journal of experimental medicine.

Criteria to make animal studies more relevant to treating human cancer.

H. Schreiber, Frank T. Wen, Steven P. Wolf, 2021, Current opinion in immunology.

Spleen cells from young but not old immunized mice eradicate large established cancers

J. Sidney, A. Sette, R. Weichselbaum, 2012, Clinical Cancer Research.

Tumor-associated fibroblasts predominantly come from local and not circulating precursors

R. Weichselbaum, V. Bindokas, H. Schreiber, 2016, Proceedings of the National Academy of Sciences.

CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

R. Schreiber, P. Monach, H. Schreiber, 1999 .

Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.

K. Tracey, H. Koeppen, H. Schreiber, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Sequential cytological changes during development of respiratory tract tumors induced in hamsters by benzo(a)pyrene-ferric oxide.

H. Schreiber, G. Saccomanno, L. Brennan, 1974, Cancer research.

Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.

H. Schreiber, yang-xin fu, M. Spiotto, 2003, Current opinion in immunology.

The terminology issue for myeloid-derived suppressor cells.

M. Colombo, H. Schreiber, Shu-Hsia Chen, 2007, Cancer research.

Inhibition of tumor growth by elimination of granulocytes

H. Schreiber, A. Toledano, L. A. Pekarek, 1995, The Journal of experimental medicine.

Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase

H. Schreiber, M. Philip, A. Schietinger, 2010, The Journal of experimental medicine.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation

Yusuke Nakamura, R. Weichselbaum, B. Engels, 2015, Clinical Cancer Research.

A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target

H. Schreiber, S. Seung, J. Urban, 1993, The Journal of experimental medicine.

A new method for pulmonary cytology in rats and hamsters.

H. Schreiber, P. Nettesheim, 1972, Cancer research.

Loss of tumor-specific and idiotype-specific immunity with age

M. Kripke, H. Schreiber, P. Flood, 1981, The Journal of experimental medicine.

Rescue of the tumor-specific immune response of aged mice in vitro.

H. Schreiber, J. Urban, 1984, Journal of immunology.

Respiratory Infections and the Pathogenesis of Lung Cancer

H. Schreiber, P. Nettesheim, D. Creasia, 1973 .

Cytokines and cancer: experimental systems.

T. Blankenstein, H. Schreiber, D. Rowley, 1991, Current opinion in immunology.

TUMOR NECROSIS FACTOR/CACHECTIN Induction of Hemorrhagic Necrosis in Normal Tissue Requires the Fifth Component of Complement (C5) BY JAY

T. Lint, H. Schreiber, L. Rothstein, 2003 .

Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.

H. Schreiber, J. Rothstein, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Fibroblasts: Dangerous travel companions

H. Schreiber, 2019, The Journal of experimental medicine.

Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

H. Shepard, B. Sugarman, H. Schreiber, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Growth Regulated Oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC Receptor-2 dependent mechanism

G. Dong, C. Waes, Zhong Chen, 2000, Oncogene.

Tumor necrosis factor: a potent mediator of macrophage-dependent tumor-cell killing.

H. Schreiber, J. Rothstein, M. Shephard, 1987, Haematology and blood transfusion.

Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells

Youjin Lee, H. Schreiber, yang-xin fu, 2003, The Journal of experimental medicine.

Experimental tumor induction in a circumscribed region of the hamster trachea: correlation of histology and exfoliative cytology.

H. Schreiber, K. Schreiber, D. Martin, 1975, Journal of the National Cancer Institute.

Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes

H. Koeppen, H. Koeppen, H. Schreiber, 1993, European journal of immunology.

Unique tumor-specific antigens.

H. Schreiber, P. Ward, H. Stauss, 1988, Annual review of immunology.

Radiation can inhibit tumor growth indirectly while depleting circulating leukocytes.

R. Weichselbaum, H. Schreiber, L. Seung, 1996, Radiation research.

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

H. Schreiber, P. Dubey, D. Rowley, 1995, Proceedings of the National Academy of Sciences of the United States of America.

This information is current as Cancer-Induced Immune Suppression Eradicate Established Tumors despite Adoptively Transferred Immune T Cells

H. Schreiber, A. Arina, David C Binder, 2013 .

Antibody recognition of a unique tumor-specific glycopeptide antigen

Lai-Xi Wang, C. MacKenzie, P. Kufer, 2010, Proceedings of the National Academy of Sciences.

MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR

D. Kranz, B. Engels, E. Roy, 2013, Cancer Immunology, Immunotherapy.

Design and characterization of a protein superagonist of IL‐15 fused with IL‐15Rα and a high‐affinity T cell receptor

H. Schreiber, J. Stone, A. Chervin, 2012, Biotechnology progress.

IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner

B. Engels, H. Schreiber, B. Jabri, 2013, Proceedings of the National Academy of Sciences.

Monoclonal Antibodies to Murine Tumors as Probes for Genetic Analysis of Individually Specific Tumor Antigens

H. Schreiber, P. Ward, P. Ward, 1988 .

Altered MHC Class I Genes Can Encode Immunogenic Antigens that Cause Tumor Rejection

H. Schreiber, H. Stauss, B. Starr, 1987 .

ISOLATION OF THE MHC GENES ENCODING THE TUMOUR‐SPECIFIC CLASS I ANTIGENS EXPRESSED ON A MURINE FIBROSARCOMA

H. Schreiber, I. Clark, R. Linsk, 1986, Journal of immunogenetics.

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

R. Schreiber, P. Monach, H. Schreiber, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Species differences in the effect of benzo(alpha)pyrene-ferric oxide on the respiratory tract of rats and hamsters.

H. Schreiber, N. Pazmiño, D. Martin, 1975, Cancer research.

Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.

C. Van Waes, P. Monach, H. Schreiber, 1996, Tissue antigens.

Selected Aspects of the Immunopharmacology of Cytokines

A. Mantovani, M. Feldmann, H. Schreiber, 1995 .

Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.

H. Koeppen, H. Schreiber, P. Ward, 1990, Cancer research.

c‐kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum

H. Schreiber, D. Rowley, K. Schreiber, 2003, European journal of immunology.

Multiple tumour-specific antigens expressed on a single tumour cell

H. Schreiber, R. D. Wortzel, C. Philipps, 1983, Nature.

Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen

H. Koeppen, H. Schreiber, H. Stauss, 1990, The Journal of experimental medicine.

Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.

H. Schreiber, D. Lancki, J. Forman, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a gene encoding a tumor-specific antigen that causes tumor rejection.

H. Schreiber, H. Stauss, B. Starr, 1987, Haematology and blood transfusion.

Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer

C. Van Waes, C. Waes, H. Schreiber, 1986, The Journal of experimental medicine.

Tumor-specific antigens and tumor-specific mutant proteins in mouse and man.

H. Koeppen, H. Schreiber, P. Ward, 1989, Haematology and blood transfusion.

Generation of antigenic variants from a nonantigenic murine tumor cell line by transfection with a gene encoding a novel tumor-specific transplantation antigen.

M. Kripke, H. Ananthaswamy, H. Schreiber, 1989, Cancer research.

Densely granulated murine NK cells eradicate large solid tumors.

B. Engels, H. Schreiber, A. Arina, 2012, Cancer research.

Tumor Growth by Elimination of Granulocytes

H. Schreiber, A. Toledano, L. A. Pekarek, 2003 .

CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells

H. Schreiber, S. Sugg, I. Brown, 2006, Cancer Immunology, Immunotherapy.

Studies on phosphorylcholine-specific T cell idiotypes and idiotype-specific immunity.

J. Kearney, R. Benca, H. Schreiber, 1980, Molecular immunology.

Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation.

L. Schumm, R. Weichselbaum, H. Schreiber, 1999, International journal of oncology.

A NOVEL MHC CLASS I MOLECULE AS A TUMOUR‐SPECIFIC ANTIGEN

H. Schreiber, H. Stauss, H. Stauss, 1986, Journal of immunogenetics.

Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones.

H. Schreiber, J. Urban, R. D. Wortzel, 1983, Journal of immunology.

Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity.

H. Schreiber, C. Mullen, D. Rowley, 1989, Cellular immunology.

Unique tumor antigens redefined as mutant tumor-specific antigens.

H. Schreiber, D. Mumberg, M. Wick, 1996, Seminars in immunology.

Tumor antigens.

H. Schreiber, J. Urban, 1992, Annual review of immunology.

Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide.

H. Schreiber, S. Meredith, P. Dubey, 1998, Journal of immunotherapy.

CD4‐POSITIVE AND B LYMPHOCYTES IN TRANSPLANTATION IMMUNITY: I. PROMOTION OF TUMOR ALLOGRAFT REJECTION THROUGH ELIMINATION OF CD4‐POSITIVE LYMPHOCYTES

B. Park, H. Schreiber, H. Stauss, 1993, Transplantation.

Unique Tumor-Specific Antigens as Altered Cell-Surface Receptors

C. Waes, H. Schreiber, H. Stauss, 1985 .

Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity.

D. Kranz, B. Engels, H. Schreiber, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Advances in Experimental Lung Cancer Research

H. Schreiber, P. Nettesheim, 1975 .

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Alexandria P. Cogdill, C. June, M. Feldman, 2016, Immunity.

Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation

M. Kripke, H. Schreiber, J. Holland, 1982, The Journal of experimental medicine.

Direct Determinationof the Influenceof the Cell Cycle on the Sijrvival of TumorCells Exposedto CytotoxicAntibodies '

M. Loken, H. Schreiber, P. Leibson, 2006 .

DirectDetermination of the Influenceof the Cell Cycleon the Sijrvival of TumorCellsExposedto CytotoxicAntibodies

M. Loken, H. Schreiber, P. Leibson, 1980 .

Nonrandom escape of tumor cells from immune lysis due to intraclonal fluctuations in antigen expression.

J. Kearney, M. Loken, H. Schreiber, 1983, Cancer research.

Mechanisms of syngeneic tumor rejection. Susceptibility of host- selected progressor variants to various immunological effector cells

M. Kripke, H. Schreiber, R. Burton, 1982, The Journal of experimental medicine.

Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infection.

H. Schreiber, P. Nettesheim, W. Lijinsky, 1972, Journal of the National Cancer Institute.

Immunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro

C. Waes, P. Monach, H. Schreiber, 1996 .

Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides

D. Kranz, H. Schreiber, H. Clausen, 2020, Proceedings of the National Academy of Sciences.

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

G. Riethmüller, H. Schreiber, D. Rowley, 2006, Hematology/oncology clinics of North America.

Inflammation as a tumor promoter in cancer induction.

H. Schreiber, M. Philip, D. Rowley, 2004, Seminars in cancer biology.

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)

D. Kranz, H. Schreiber, J. Stone, 2012, Oncoimmunology.

The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68

J. Shabanowitz, D. Hunt, V. Engelhard, 1997, The Journal of experimental medicine.

A unique tumor antigen produced by a single amino acid substitution.

P. Monach, H. Schreiber, S. Meredith, 1995, Immunity.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

R. Weichselbaum, Hua Yu, N. Hübner, 2017, Nature.

Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer

D. Munn, R. Hoffman, B. Engels, 2013, Cancer Immunology Research.

Bystander elimination of antigen loss variants in established tumors

H. Schreiber, M. Spiotto, D. Rowley, 2004, Nature Medicine.

A Mutant Chaperone Converts a Wild-Type Protein into a Tumor-Specific Antigen

P. Azadi, H. Schreiber, S. Meredith, 2006, Science.

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Cathleen Brdlik, H. Shepard, H. Schreiber, 2008, The Journal of clinical investigation.

Targeting cancer-specific mutations by T cell receptor gene therapy.

T. Blankenstein, W. Uckert, M. Leisegang, 2015, Current opinion in immunology.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

John Sidney, Alessandro Sette, David M Kranz, 2013, Cancer cell.

Heritable and non-heritable variations in the phenotype of myeloma cells as detected by a fluorescence-activated cell sorter.

M R Loken, M. Loken, H. Schreiber, 1979, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Footprinting of individual tumors and their variants by constitutive cytokine expression patterns.

R. Weichselbaum, M. Beckett, H. Schreiber, 1993, Cancer research.

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer

Jianhua Huang, Hans Schreiber, David W Piston, 2013, Oncoimmunology.

Ribosomal versus non‐ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells

H. Schreiber, M. Philip, A. Schietinger, 2010, Immunology.

Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity

H. Schreiber, J. Urban, 1983, The Journal of experimental medicine.

Targeting stroma to treat cancers.

B. Engels, H. Schreiber, D. Rowley, 2012, Seminars in cancer biology.

Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells

H. Koeppen, H. Schreiber, P. Ward, 1989, The Journal of experimental medicine.

Rapid development of bronchiolo-alveolar squamous cell tumors in rats after intratracheal injection of 3-methylcholanthrene.

H. Schreiber, P. Nettesheim, D. Martin, 1972, Journal of the National Cancer Institute.

Changes in susceptibility to cytotoxic antibody among tumor cells surviving exposure to chemotherapeutic agents.

M. Loken, H. Schreiber, P. Leibson, 1982, Cancer research.

Genetic changes occurring in established tumors rapidly stimulate new antibody responses

M. Reth, H. Schreiber, M. Spiotto, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Tracking the common ancestry of antigenically distinct cancer variants.

H. Schreiber, W. Kast, K. Schreiber, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genetically Engineered Vaccines Comparison of Active versus Passive Immunotherapy against Solid Tumors a

H. Koeppen, H. Schreiber, Sunanda R Singh, 1993, Annals of the New York Academy of Sciences.

Pecking order among tumor‐specific antigens

C. Van Waes, H. Schreiber, J. Urban, 1984, European journal of immunology.

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Bin Zhang, H. Schreiber, T. Karrison, 2008, The Journal of clinical investigation.

Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

D. Kranz, Bin Zhang, H. Schreiber, 2008, Cancer research.

Suppression of myeloma growth in vitro by anti-idiotypic antibodies: inhibition of DNA synthesis and colony formation.

H. Schreiber, P. Leibson, 1978, Journal of the National Cancer Institute.

The role of stroma in immune recognition and destruction of well-established solid tumors.

H. Schreiber, yang-xin fu, D. Rowley, 2006, Current opinion in immunology.

Role of TGF‐β in immune‐evasion of cancer

H. Schreiber, D. Rowley, C. Beck, 2001 .

Direct determination of the influence of the cell cycle on the survival of tumor cells exposed to cytotoxic antibodies.

M. Loken, H. Schreiber, P. Leibson, 1980, Cancer research.

Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors.

Y. Ron, H. Schreiber, P. Flood, 1987, Journal of immunology.

Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes.

H. Schreiber, P. Flood, C. Philipps, 1980, Journal of immunology.

Idiotype network interactions in tumor immunity.

H. Schreiber, Hans Schreiber, 1984, Advances in cancer research.

Suppression by autogenous complementary idiotypes: the priority of the first response

H. Schreiber, D. Rowley, I. Lorbach, 1976, The Journal of experimental medicine.

Suppression of tumor rejection by autologous anti-idiotypic immunity.

M. Kripke, H. Schreiber, D. Rowley, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets.

H. Schreiber, V. Bindokas, Steven P. Wolf, 2020, Experimental cell research.

Epidemiology and biology of relapse after stem cell transplantation

N. Kröger, M. Horowitz, O. Heidenreich, 2018, Bone Marrow Transplantation.

Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein

Christopher A. Lazarski, G. Beck-Engeser, H. Schreiber, 2000, The Journal of experimental medicine.

Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains

Thomas M. Schmitt, B. Baker, P. Greenberg, 2011, Gene Therapy.

Stepwise immunologic selection of antigenic variants during tumor growth.

M. Kripke, H. Schreiber, J. Urban, 1986, Journal of immunology.

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

Youjin Lee, H. Schreiber, A. Chong, 2005, The Journal of experimental medicine.

Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication

R. Weichselbaum, T. Karrison, H. Schreiber, 2017, Cancer Immunology Research.

Point Mutation in Essential Genes with Loss or Mutation of the Second Allele

R. Espinosa, M. L. Le Beau, G. Beck-Engeser, 2001, The Journal of experimental medicine.

A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody

Yoshiki Narimatsu, H. Schreiber, S. Vakhrushev, 2019, Glycobiology.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.

H. Schreiber, David C Binder, 2014, Cancer research.

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.

M. Nishimura, H. Schreiber, yang-xin fu, 2002, Immunity.

Role of TGF-beta in immune-evasion of cancer.

H. Schreiber, D. Rowley, C. Beck, 2001, Microscopy research and technique.

Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors

R. Tennant, Lieping Chen, G. Beck-Engeser, 2004, Oncogene.

Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors

E. Pamer, K. Kiyotani, M. Leisegang, 2019, Cancer Immunology Research.

Immunodominance and tumor escape.

H. Schreiber, H Schreiber, W. Kast, 2002, Seminars in cancer biology.

Tumor Stroma and the Antitumor Immune Response

Bin Zhang, H. Schreiber, D. Rowley, 2008 .

Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell.

C. June, D. Kranz, M. Leisegang, 2019, JCI insight.

Adoptively Transferred Immune T Cells Eradicate Established Tumors despite Cancer-Induced Immune Suppression

T. Karrison, H. Schreiber, A. Arina, 2014, The Journal of Immunology.

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

R. Weichselbaum, D. Kranz, Bin Zhang, 2007, The Journal of experimental medicine.

Antigens Oligoclonal T-Cell Response to a Tumor with Multiple Target DNA Sequence Analysis of T-Cell Receptor Genes Reveals an Updated

H. Schreiber, S. Seung, J. Urban, 2006 .

DNA Sequence Analysis of T-Cell Receptor Genes Reveals an Oligoclonal T-Cell Response to a Tumor with Multiple Target Antigens 1

H. Schreiber, S. Seung, J. Urban, 2006 .

Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.

H. Schreiber, M. Spiotto, 2005, Cancer immunity.

CD4+ AND B LYMPHOCYTES IN TRANSPLANTATION IMMUNITY: II. AUGMENTED REJECTION OF TUMOR ALLOGRAFTS BY MICE LACKING B CELLS

H. Schreiber, D. Rowley, Paul A. Moach, 1993, Transplantation.

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

H. Schreiber, Sunanda R Singh, D. Rowley, 1992, The Journal of experimental medicine.

A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth

Ronald A. Thisted, Hans Schreiber, R. Thisted, 2012, Oncoimmunology.

Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium

R. Hoffman, H. Schreiber, A. Arina, 2016, Oncoimmunology.

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies

H. Schreiber, David C Binder, 2013, Oncoimmunology.

Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

R. Weichselbaum, N. Khodarev, H. Schreiber, 2011, Cancer immunity.

Design of T cell receptor libraries with diverse binding properties to examine adoptive T cell responses

D. Kranz, B. Engels, E. Roy, 2012, Gene Therapy.

A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity.

M. Nishimura, H. Schreiber, G. Callender, 2005, Cancer letters.

Recurrence of Intracranial Tumors following Adoptive T Cell Therapy Can Be Prevented by Direct and Indirect Killing Aided by High Levels of Tumor Antigen Cross-Presented on Stromal Cells1

D. Kranz, E. Roy, H. Schreiber, 2009, The Journal of Immunology.

Stromal Cells Levels of Tumor Antigen Cross-Presented on by Direct and Indirect Killing Aided by High Adoptive T Cell Therapy Can Be Prevented Recurrence of Intracranial Tumors following

D. Kranz, E. Roy, H. Schreiber, 2009 .

Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.

D. Kranz, B. Engels, H. Schreiber, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells

C. Van Waes, J. Friedman, H. Schreiber, 2019, Clinical Cancer Research.

Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.

Larry R. Smith, J. K. Pullen, H. Schreiber, 2002, Cancer research.

Tumor-Specific Antigens on Experimental Tumors

H. Schreiber, H. Stauss, 1986 .

Tumor growth and evasion of immune destruction: UV-induced tumors as a model

H. Schreiber, C. Mullen, 1985, Survey of immunologic research.

Surveillance role of various leukocytes in preventing the outgrowth of potentially malignant cells.

H. Schreiber, J. Urban, 1984, Contemporary topics in immunobiology.

Tumor-specific immune responses.

H. Schreiber, 2008, Seminars in immunology.

Tar geting the Cancer-AssociatedTn-Glycoformof theMembraneMucinMUC 1 Control Adenocarcinoma Highlights

David M. Kranz, Jennifer D. Stone, Brian Keith, 2016 .

Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.

J. Bluestone, H. Schreiber, J. Ellenhorn, 1990, Journal of immunology.

Host-tumor interactions in immunosurveillance against cancer.

H. Schreiber, J. Urban, 1988, Progress in experimental tumor research.

Immunological enhancement of primary tumor development and its prevention.

H. Schreiber, D. Rowley, T. Wu, 2000, Seminars in cancer biology.

Major Histocompatibility Complex Class I and Unique Antigen Expression by Murine Tumors That Escaped from CD8+ T-Cell-dependent Surveillance1 Analysis of Class Antigens. The

H. Schreiber, P. Ward, D. Rowley, 2006 .

Major Histocompatibility Complex Class I and Unique Antigen Expression by Murine Tumors That Escaped from CD 8 + T-Cell-dependent Surveillance 1

H. Schreiber, P. Ward, D. Rowley, 2006 .

Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells

C. Van Waes, H. Schreiber, J. Rothstein, 1986, The Journal of experimental medicine.

Long-Term Suppression of Tumor Growth by TNF Requires a Stat1- and IFN Regulatory Factor 1-Dependent IFN-γ Pathway but Not IL-12 or IL-181

J. Dignam, T. Blankenstein, H. Schreiber, 2004, The Journal of Immunology.

Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.

H. Schreiber, J. Urban, R. D. Wortzel, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Multiple cancers. Tumor burden permits the outgrowth of other cancers

C. Van Waes, C. Waes, H. Schreiber, 1985, The Journal of experimental medicine.

Awakening Immunity

Hans Schreiber, H. Schreiber, D. Rowley, 2010, Science.

Cooperation of genes in HPV16 E6/E7-dependent cervico-vaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.

Yusuke Nakamura, R. Weichselbaum, G. Beck-Engeser, 2020, Carcinogenesis.

TCR–pMHC bond conformation controls TCR ligand discrimination

E. Adams, H. Schreiber, Jian Qin, 2019, Cellular & Molecular Immunology.

Advances in Brief Footprinting of Individual Tlimors and Their Variants by Constitutive Cytokine Expression Patterns 1

R. Weichselbaum, M. Beckett, H. Schreiber, 2006 .

Cytokines as effectors in tumor immunity

H. Schreiber, J. Rothstein, M. Teng, 1990 .

Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model

E. Roy, T. Fan, P. Hergenrother, 2023, Journal for ImmunoTherapy of Cancer.

Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression.

M. Loken, H. Schreiber, P. Leibson, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Active immunization against cancer cells: impediments and advances.

H. Schreiber, W. Kast, M. Velders, 1998, Seminars in oncology.

Bronchial metaplasia as a benign or premalignant lesion. I. Cytologic and ultrastructural discrimination between acute carcinogen effects and toxin-induced changes.

M. Bibbo, G. Wied, H. Schreiber, 1979, Acta cytologica.

Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombination.

H. Schreiber, M. Spiotto, 2006, Journal of immunological methods.

TCR-pMHC bond length controls TCR ligand discrimination

E. Adams, H. Schreiber, Jian Qin, 2018, bioRxiv.

Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction.

H. Juhl, M. Neumaier, H. Kalthoff, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase

H. Schreiber, M. Philip, A. Schietinger, 2010, The Journal of experimental medicine.

Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

J. Bluestone, Lieping Chen, H. Koeppen, 1997, The Journal of experimental medicine.

Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent.

M. Loken, H. Schreiber, P. Leibson, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

Youjin Lee, H. Schreiber, A. Chong, 2005, The Journal of experimental medicine.

Powered by the California Digital Library University of California ANIMALS BEARING MALIGNANT GRAFTS REJECT NORMAL GRAFTS THAT EXPRESS THROUGH GENE TRANSFER THE SAME ANTIGEN

H. Koeppen, S. Ross, H. Schreiber, 2003 .